Eudaemon Technologies has completed an oversubscribed $4.5 million Seed funding round, opened an additional $10 million capital raise, and launched a manufacturing facility in Sydney as it prepares its hydrogel condom technology for clinical development and global commercialization.
The Australian clinical-stage medtech company has spent more than a decade developing a hydrogel-based alternative to conventional latex and synthetic condoms. Its lead product uses a material that is 50% water, inherently wet, and latex-free and is designed to more closely replicate certain mechanical and thermal properties of human tissue.
The technology originated from research supported through the Bill & Melinda Gates Foundation’s Grand Challenges initiative. Eudaemon has since developed manufacturing processes for the hydrogel product, secured 61 granted patents including patents in the U.S. and China, and completed an initial clinical study.
The company has now opened an advanced manufacturing facility in Annandale, Sydney, as it prepares for pivotal clinical trials, additional regulatory work, and manufacturing scale-up.
The completed $4.5 million Seed round will support continued manufacturing development and preparations for clinical trials and international regulatory clearances.
Eudaemon has also opened a separate $10 million funding round intended to finance clinical trials, regulatory clearances, expanded manufacturing capacity, and commercialization. The company is targeting a commercial launch in 2028, with Australia and the United States identified as priority markets.
Alongside the financing, Eudaemon has begun building its consumer brand through a campaign called Operation International Relations, developed with creative studio and brand incubator ST JULES. The campaign is intended to begin building awareness in Australia and the U.S. well ahead of commercialization.
The company is led by Executive Chairman and Co-Founder Nick Northcott and Co-Founder Dr. Simon Cook. Eudaemon said its longer-term strategy includes global commercialization and potential licensing partnerships for its hydrogel barrier technology.
KEY QUOTES:
“We’ve spent more than a decade working through the science, engineering and manufacturing required to reinvent the condom. A lot of that work has happened quietly. We’ve developed the material, built the machines, tested the product and worked out how to manufacture something that hasn’t been made before.”
“We’re going after a very large global market with technology developed here in Australia. The response to the seed round was a strong vote of confidence in the technology and the team. The $10 million raise will fund the next body of work required to get the product through the regulatory process, increase manufacturing capacity and prepare for market.”
Nick Northcott, Executive Chairman And Co-Founder Of Eudaemon Technologies
